AIM
TRAW icon

Alambic Investment Management’s Traws Pharma TRAW Stock Holding History

Alambic Investment Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2
Closed -$36K – 601
2016
Q3 		$36K Buy
+2
New +$40.8K 0.01% 502

Other funds holding TRAW

TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alambic Investment Management's TRAW Position: Q4 2016 in Review

Alambic Investment Management sold out of Traws Pharma (TRAW) in Q4 2016, closing a stake of 2 shares — an estimated $36K sold.

Alambic Investment Management first reported a position in TRAW in Q3 2016 and held it in 1 quarter. The position peaked at $36K in Q3 2016. 10 funds tracked by Wall St. Rank hold TRAW as of Q4 2016.

  • Alambic Investment Management reported no remaining Traws Pharma position as of Q4 2016 after selling out during the quarter.
  • Alambic Investment Management sold 2 Traws Pharma shares in Q4 2016, an estimated $36K.
  • Alambic Investment Management first reported a position in Traws Pharma in Q3 2016 and held it in 1 quarter.
  • Alambic Investment Management's Traws Pharma position peaked at $36K in Q3 2016.
  • 10 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2016.

Based on Alambic Investment Management's 13F filing for Q4 2016, filed 3 Feb 2017.